Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moleculin Biotech (MBRX) Cash from Investing Activities (2016 - 2024)

Moleculin Biotech's Cash from Investing Activities history spans 9 years, with the latest figure at -$13000.0 for Q2 2024.

  • Quarterly results put Cash from Investing Activities at -$13000.0 for Q2 2024, up 13.33% from a year ago — trailing twelve months through Mar 2025 was -$13000.0 (up 89.52% YoY), and the annual figure for FY2024 was -$13000.0, up 89.52%.
  • Cash from Investing Activities for Q2 2024 was -$13000.0 at Moleculin Biotech, up from -$81000.0 in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of -$2000.0 in Q1 2020 to a low of -$340000.0 in Q3 2020.
  • The 5-year median for Cash from Investing Activities is -$18000.0 (2020), against an average of -$54272.7.
  • Peak annual rise in Cash from Investing Activities hit 86.67% in 2020, while the deepest fall reached 4150.0% in 2020.
  • Year by year, Cash from Investing Activities stood at -$14000.0 in 2020, then crashed by 35.71% to -$19000.0 in 2021, then tumbled by 221.05% to -$61000.0 in 2022, then plummeted by 32.79% to -$81000.0 in 2023, then soared by 83.95% to -$13000.0 in 2024.
  • According to Business Quant data, Cash from Investing Activities over the past three periods came in at -$13000.0, -$81000.0, and -$28000.0 for Q2 2024, Q4 2023, and Q3 2023 respectively.